# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lorraine Hansberry (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML034-SYN-TD
- Date: 1963-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odette Marchetti-Fields, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Burning, boring pain under the breastbone and through to the back for about two months, worse after meals and at night; black stools on and off for three weeks; two near-fainting spells; weight down 5 kg **S**
- An urgent care clinic put the pain down to indigestion and stress five weeks ago; she does not want it put down to stress again, and wants the cause found and told to her plainly, whatever it is **S**
- She wants to finish her play and to keep writing through whatever treatment she needs, with a clear head **S**

## Your goals

- Endoscopy and pancreas-protocol CT within one week, tissue diagnosis and biliary drainage within two weeks, and a tumor board plan within three weeks of presentation. Target: 1963-05-04. Recorded outcome: Endoscopy in two days, CT in three, EUS biopsy and stent in one week, tumor board in nine days, consultation at two weeks. **S**
- Germline genetic testing with counseling and tumor molecular profiling resulted before surgery. Target: 1963-06-29. Recorded outcome: Germline panel negative; tumor KRAS G12D, microsatellite stable, no targetable alteration. **S**
- Six cycles of modified FOLFIRINOX before surgery with no delay of more than one week. Target: 1963-08-10. Recorded outcome: Six cycles; one dose reduction of irinotecan after diarrhea; CT shows a partial response. **S**
- Resection with clear margins if restaging shows no progression. Target: 1963-10-05. Recorded outcome: Pancreaticoduodenectomy with vein resection; margins clear (R0). **S**
- Pain 3 out of 10 or less with a clear head for writing. Target: 1963-06-29. Recorded outcome: Pain 1 to 2 out of 10 on oxycodone 5 mg once or twice a day. **S**
- Weight kept within 5 percent of the weight at diagnosis through chemotherapy, with enzyme replacement and dietitian support. Target: 1963-08-10. Recorded outcome: Weight 54.2 kg before surgery, 2 percent below the weight at diagnosis. **S**
- PHQ-9 below 10 throughout treatment, with support she chooses and palliative care alongside cancer treatment. Target: 1963-10-05. Recorded outcome: PHQ-9 between 6 and 8. **S**

## What we agreed to do

- Medical oncology consultation within two weeks to review the endoscopy, CT and any biopsy with her and plan treatment if cancer is found. Guideline: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016) **S**
- Urgent work-up of epigastric pain with weight loss, anemia and new diabetes: upper endoscopy within days, pancreas-protocol CT of the abdomen with CT of the chest, blood count, ferritin, liver tests, lipase and A1c; pantoprazole until the endoscopy; return at once for fresh black stools, fainting or yellow eyes. Guideline: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Noel M, Fiscella K. Disparities in Pancreatic Cancer Treatment and Outcomes. Health Equity 2019;3(1):532-540 (PMID 31663065) (2019) **S**
- Intravenous iron for iron deficiency anemia from blood loss, with a blood count at each visit. Guideline: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026) **S**
- Tissue and staging: EUS-guided biopsy with extra cores for molecular profiling, biliary drainage with a metal stent, CA 19-9 after the bilirubin is normal, and review at the pancreatic tumor board. Guideline: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016) **S**
- Germline genetic testing with counseling for every patient with pancreatic cancer, and tumor molecular profiling (including KRAS, BRCA1, BRCA2, PALB2, mismatch repair, NTRK and NRG1); cascade testing offered to blood relatives only if a germline variant is found. Guideline: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Sohal DPS, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol 2020;38(27):3217-3230 (PMID 32755482) (2020); Stoffel EM, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2019;37(2):153-164 (PMID 30457921) (2019) **S**
- Modified FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2 over 46 hours) every two weeks for six cycles (three months) before surgery through a port, with pegfilgrastim, olanzapine-based antiemetic prevention that spares dexamethasone because of her diabetes, loperamide for late diarrhea, and neuropathy checks; CA 19-9 every two cycles and restaging CT after four and six cycles; hepatitis B, hepatitis C and HIV screening and a pregnancy test first. Guideline: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016); Khorana AA, et al. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. J Clin Oncol 2019;37(23):2082-2088 (PMID 31180816) (2019); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (PMID 32658626) (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (PMID 32663120) (2020); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020;38(31):3698-3715 (PMID 32716741) (2020) **S**
- Palliative care from the day of diagnosis, alongside cancer treatment: symptom control, a serious illness conversation, and planning that keeps her writing at the center; oxycodone 5 mg as needed with a bowel regimen, and EUS-guided celiac plexus neurolysis if pain becomes severe. Guideline: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024) **S**
- Nutrition: dietitian review at each phase, pancrelipase with every meal and snack, small frequent meals, weight at every visit. Guideline: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026) **S**
- Diabetes due to pancreatic disease: home glucose checks, A1c every three months, glucose checks before each cycle; insulin rather than oral agents if treatment is needed after surgery; dilated eye examination and urine albumin-to-creatinine ratio at diagnosis. Guideline: American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and anemia monographs (2026) **S**
- Venous thromboembolism: Khorana score recorded (3: pancreatic primary and hemoglobin below 10 g/dL); prophylactic apixaban offered once the duodenal bleeding has settled; enoxaparin for four weeks after surgery. Guideline: Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Carrier M, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer (AVERT). N Engl J Med 2019;380(8):711-719 (PMID 30511879) (2019) **S**
- Fertility and contraception: oncofertility counseling before chemotherapy, a pregnancy test before treatment, and effective non-estrogen contraception if she becomes sexually active during treatment. Guideline: Oktay K, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018;36(19):1994-2001 (PMID 29620997) (2018) **S**
- Pylorus-preserving pancreaticoduodenectomy with resection of the involved segment of the superior mesenteric vein after restaging shows no progression. Guideline: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016) **S**
- Chemotherapy after surgery to complete about six months of treatment: six cycles of fluorouracil, leucovorin and irinotecan every two weeks, without oxaliplatin because of neuropathy; insulin glargine adjusted to home glucose readings; apixaban prophylaxis resumed during chemotherapy; surveillance afterwards with history, examination, CA 19-9 and CT every three to six months for two years. Guideline: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016); Khorana AA, et al. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. J Clin Oncol 2019;37(23):2082-2088 (PMID 31180816) (2019); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023) **S**
- Distress and depression screening at each visit, plain explanations with written information, and support she chooses; she decides who is told and who receives each note. Guideline: Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); Depression and Suicide Risk in Adults: Screening (2023) **S**

## Follow-up

- 1963-04-20: Two months of epigastric and back pain, weight loss, black stools and near-fainting in a woman of 32: examination, blood tests, and urgent upper endoscopy and pancreas-protocol CT **S**
- 1963-05-04: Diagnosis of pancreatic adenocarcinoma: tumor board plan, medical oncology consultation, genetic counseling, early palliative care, and planning of chemotherapy before surgery **S**
- 1963-06-29: Day 1 of cycle 4 of modified FOLFIRINOX: toxicity review, genetic and tumor profiling results, thromboprophylaxis, nutrition and mood **S**
- 1963-08-10: After six cycles: restaging CT and CA 19-9, decision for surgery, and preparation for pancreaticoduodenectomy **S**
- 1963-10-05: Six weeks after pancreaticoduodenectomy: pathology, diabetes and enzyme replacement after surgery, and the plan for chemotherapy after surgery **S**
- 1963-10-21: Periodic adult preventive visit during chemotherapy after surgery **S**

This teaching document does not replace care from a qualified clinician.
